Observational Study of Effectiveness and Safety of Recombinant Zoster Vaccine (Shingrix)® in Moderately-to-Severely Active Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) Patients Treated with Tofacitinib (Xeljanz)® in Real- World Clinical Care Settings

19/01/2024
06/12/2024
EU PAS number:
EUPAS48998
Study
Ongoing
Documents
Study protocol
Initial protocol
English (2.46 MB - PDF) View document
Study results
Study report
Other information